Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear receptor subfamily 5, group A, member 1 | Starlite/ChEMBL | References |
Homo sapiens | nuclear receptor subfamily 5, group A, member 2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | FTZ F1 nuclear receptor protein | nuclear receptor subfamily 5, group A, member 1 | 461 aa | 460 aa | 32.6 % |
Brugia malayi | Ligand-binding domain of nuclear hormone receptor family protein | nuclear receptor subfamily 5, group A, member 2 | 469 aa | 431 aa | 22.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0285 | 0.2062 | 0.5 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0285 | 0.2062 | 1 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0285 | 0.2062 | 0.1401 |
Plasmodium falciparum | DNA gyrase subunit B | 0.0515 | 0.4983 | 0.3679 |
Schistosoma mansoni | amidase | 0.0303 | 0.2289 | 1 |
Echinococcus granulosus | FTZ F1 alpha | 0.0489 | 0.465 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0285 | 0.2062 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.0055 | 0.0242 |
Trypanosoma brucei | DNA topoisomerase ii | 0.0285 | 0.2062 | 1 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0303 | 0.2289 | 1 |
Brugia malayi | amidase | 0.0303 | 0.2289 | 1 |
Schistosoma mansoni | DNA topoisomerase II | 0.0285 | 0.2062 | 0.901 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0285 | 0.2062 | 0.5 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0285 | 0.2062 | 0.4435 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0285 | 0.2062 | 0.5 |
Giardia lamblia | DNA topoisomerase II | 0.0261 | 0.1749 | 0.5 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0303 | 0.2289 | 0.4922 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0285 | 0.2062 | 0.901 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.0285 | 0.2062 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.0055 | 0.0242 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0285 | 0.2062 | 0.901 |
Brugia malayi | Probable DNA topoisomerase II | 0.0285 | 0.2062 | 0.901 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0285 | 0.2062 | 0.5 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0303 | 0.2289 | 0.4922 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.0285 | 0.2062 | 0.901 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0285 | 0.2062 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0303 | 0.2289 | 1 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0285 | 0.2062 | 0.901 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.0515 | 0.4983 | 0.3679 |
Schistosoma mansoni | fatty-acid amide hydrolase | 0.0303 | 0.2289 | 1 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0303 | 0.2289 | 1 |
Mycobacterium leprae | Probable DNA gyrase (subunit A) GyrA (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) | 0.0397 | 0.3482 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 5.6 | Agonist activity at human LRH-1 receptor assessed as TIF2 737-757 peptide recruitment by TR-FRET assay relative to control | ChEMBL. | 21391689 |
EC50 (functional) | = 6.3 | Agonist activity at human SF-1 assessed as DAX1 1-23 peptide recruitment by TR-FRET assay relative to control | ChEMBL. | 21391689 |
Ratio (functional) | = 0.17 | Agonist activity at human LRH-1 receptor assessed as TIF2 737-757 peptide recruitment by TR-FRET assay | ChEMBL. | 21391689 |
Ratio (functional) | = 0.55 | Agonist activity at human SF-1 assessed as DAX1 1-23 peptide recruitment by TR-FRET assay | ChEMBL. | 21391689 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.